Clinical Trial Update: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating GSK2636771 in cancers with PTEN loss under the MATCH program; the study is active but not recruiting and results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic and Lymphoid Cell Neoplasm
• Lymphoma
• Malignant Solid Neoplasm
• Multiple Myeloma

Drugs mentioned

• GSK2636771

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-20